UBS Downgrades Chemours to Neutral, Lowers Price Target to $18
Benzinga Newsdesk 3 months ago
NewsDowngradesAnalyst RatingsPrice Target
UBS analyst Joshua Spector downgrades Chemours (NYSE:CC) from Buy to Neutral and lowers the price target from $29 to $18.
UBS analyst Joshua Spector downgrades Chemours (NYSE:CC) from Buy to Neutral and lowers the price target from $29 to $18.